The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease and ulcerative colitis. Guselkumab is currently approved to treat plaque psoriasis and psoriatic arthritis. However, clinical studies have shown that guselkumab is also efficacious in treating adults with moderately to severely active Crohn’s disease and UC who have not responded well to other treatments or experienced unacceptable side effects. Guselkumab can be administered either by intravenous infusion or injection for the initial treatment of Crohn’s disease. For UC, initial treatment will be administered via an intravenous infusion. The approval was granted on to Janssen-Cilag Limited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Unusually active option classes on open May 15th
- U.S. biotech companies debate relocating trials outside U.S., Reuters reports
- Johnson & Johnson’s Strong Market Position and Growth Potential Highlighted by Tremfya’s Success in IBD Market
- UnitedHealth suspends outlook, Under Armour reports Q4 beat; Morning Buzz
- Halozyme, J&J slide as analyst cuts rating on CMS draft guidance